# Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer

> **NCT00022594** · PHASE2 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 50 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** liposomal lurtotecan

## Key facts

- **NCT ID:** NCT00022594
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** 2002-08
- **Final completion:** —
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2012-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00022594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00022594, "Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00022594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*